Group 1 - The core point of the news is that Shandong High-speed Group and Shandong University Capital signed a "Joint Action Agreement" to maintain a unified action relationship in the management of Shanda Diwei Software Co., Ltd, resulting in a combined voting power of 29.58% [65][67] - The agreement does not trigger a mandatory takeover and does not change the controlling shareholder or actual controller of the company, which remains Shandong High-speed Group and the State-owned Assets Supervision and Administration Commission of Shandong Province [66][77] - The agreement aims to leverage the resource advantages of both parties to enhance collaboration and improve the company's development [67] Group 2 - As of the date of the report, Shandong High-speed Group holds 24.59% of the shares, while Shandong University Capital holds 4.99%, maintaining their respective voting rights [67] - The agreement includes provisions for joint exercise of shareholder rights, ensuring that both parties will act in concert during shareholder meetings and board decisions [68][70] - The agreement is valid for three years and will automatically renew unless either party objects [75] Group 3 - The report confirms that there are no restrictions on the rights of the shares involved in this equity change, such as pledges or freezes [27] - There are no plans for significant changes to the company's main business, asset sales, mergers, or major adjustments to the management structure within the next 12 months [29][30] - The parties involved have committed to maintaining the independence of Shanda Diwei's operations, assets, and finances, ensuring no interference from the controlling entities [33][34]

Core Viewpoint - Shenzhen Core Medical Technology Co., Ltd. is preparing for an IPO on the Sci-Tech Innovation Board, focusing on innovative medical devices in the artificial heart sector to address the urgent clinical needs of over 10 million heart failure patients in China [2]. Company Overview - Core Medical is a national high-tech enterprise specializing in the research, development, production, and sales of implantable and interventional artificial heart products [2]. - The company is controlled by Yu Shunzhou, who holds 21.79% of the shares directly and an additional 0.09% indirectly through Shenzhen Xinfuh [2]. Shareholding Structure - Yu Shunzhou controls a total of 29.14% of the voting rights in the company, including shares held through a partnership [2]. - Yu Shunzhou's brother, Yu Shunli, was initially registered to hold shares on behalf of Yu Shunzhou but has not made the required capital contributions [2][4]. Capital Contributions - The registered capital of Core Medical was set at 10 million yuan, with all contributions from Yu Shunzhou made in 2019 totaling 492 million yuan [6]. - The contributions were made in cash from personal funds, and the total amount of 1,000 million yuan was fully paid [6]. Relationship Between Shareholders - Yu Shunzhou and Yu Shunli are considered acting in concert due to their close familial relationship, as defined by regulations [6]. - Yu Shunli has committed to lock up his indirectly held shares in accordance with the same requirements as the actual controller, Yu Shunzhou [6]. Management Background - Yu Shunli has held various financial management positions in different companies and has been involved with Core Medical since 2019 [7]. - Yu Shunzhou has an extensive academic background in mechanical engineering and has held several senior engineering roles before becoming the chairman and general manager of Core Medical [8][9].

Core Viewpoint - Longchen Technology Co., Ltd. is preparing for an initial public offering on the Beijing Stock Exchange, with a focus on its BOPP film materials business, and has responded to the second round of inquiry letters from the exchange [2]. Company Overview - Longchen Technology was established in 2003 and specializes in the research, production, and sales of BOPP film materials, which are categorized into base films and metallized films. The company has been listed on the New Third Board since 2015 [2]. Shareholding Structure - As of the signing date of the prospectus, Lin Meiyun directly holds 53.66 million shares, representing 52.61% of the company, and controls an additional 1.47% through her role as the executive partner of Zeming Xincheng, totaling 54.08% ownership. The fourth largest shareholder, Lin Weiliang, holds 3.48% and is Lin Meiyun's brother [2][3]. Inquiry from the Beijing Stock Exchange - The Beijing Stock Exchange has requested Longchen Technology to clarify the relationship between Lin Weiliang and Lin Meiyun, including whether Lin Weiliang is considered a concerted actor with Lin Meiyun, and to provide details on shareholding lock-up and reduction arrangements post-listing [2]. Lin Weiliang's Background - Lin Weiliang has been involved with the company since 2010, acquiring shares through stock transfers. He previously served as a director and is currently the assistant to the chairman, focusing on daily operations and decision implementation [3][4]. Clarification on Concerted Action - Longchen Technology does not recognize Lin Weiliang as a concerted actor with Lin Meiyun due to several reasons, including the absence of a concerted action agreement, independent attendance at board meetings, and a lack of involvement in major decision-making processes [4][5]. Commitment Letters - Both Lin Weiliang and Lin Meiyun have issued commitment letters stating that there is no concerted action relationship, and Lin Weiliang has also provided a commitment regarding share lock-up and reduction [4]. Management Background - Lin Meiyun, born in August 1969, has a background in business management and has held various executive positions in multiple companies since 1998, including her current roles at Longchen Technology and other related firms [5].

Core Viewpoint - Dongtong Tui (300379) has completed its last trading day on January 21, 2026, and announced its delisting. However, during the 15-day delisting adjustment period, there has been significant capital accumulation, raising questions about potential control disputes and coordinated actions among investors [1]. Group 1: Trading Activity - Guotai Haitong Securities Fuyang Xihu Avenue branch has been aggressively buying Dongtong Tui shares for 14 consecutive trading days, accumulating a total purchase amount of 86.12 million yuan, with only 875 yuan in sales [1][3]. - The estimated shareholding from this branch reached 51.28 million shares, accounting for 9.19% of the total share capital, surpassing the 5% disclosure threshold and the controlling shareholder Huang Yongjun's 7.66% stake [1][3]. - The buying activity has been characterized by a steady increase in daily purchase amounts, peaking at 9.49 million yuan on January 19, 2026 [3]. Group 2: Institutional Participation - Multiple institutional seats have appeared on the trading leaderboard, with significant net purchases, including 7.89 million yuan on January 21, 2026, and 1.49 million yuan on January 20, 2026 [4]. - The total net purchase amount from the leaderboard during the 15-day period reached 123 million yuan, indicating a fierce competition for shares [4]. Group 3: Potential Control Disputes - The capital accumulation around Dongtong Tui resembles previous cases, such as Guangyi Tui, where coordinated buying led to significant shareholding increases without proper disclosure [5]. - There are indications that the buying may involve multiple accounts to circumvent regulatory limits on daily purchases, suggesting potential collusion among investors [6][7]. - The weak control structure of Dongtong Tui, with the controlling shareholder's stake being only 7.66%, presents an opportunity for capital intervention and control disputes [9]. Group 4: Financial Health - Despite its delisting due to major violations, Dongtong Tui's financial situation appears relatively stable, with total assets of 3.435 billion yuan and liabilities of only 381 million yuan as of September 30, 2025 [9]. - The company reported a revenue of 419 million yuan in the first three quarters of 2025, with a gross margin of 72.86%, although it still recorded a net loss of 83.99 million yuan [9].

Core Viewpoint - The announcement details the renewal of the "Consistent Action Agreement" among the actual controllers of Jiangsu Shuoshi Biotechnology Co., Ltd., aimed at ensuring stable governance and operational continuity of the company [1][2]. Group 1: Background of the Agreement - The actual controllers, Fang Yongsheng, Liang Xilin, and Wang Guoqiang, collectively control 27.53% and 3.81% of the company's shares through various partnerships, with Fang Yongsheng serving as the honorary chairman and Wang Guoqiang as the chairman and general manager [1][2]. - The agreement was initially signed before the company's IPO and has been renewed on December 5 for the years 2022, 2023, 2024, and now 2025 to promote stable development based on shared goals [2]. Group 2: Main Content of the Agreement - The parties agree to act consistently in decision-making regarding the company, maintaining alignment in exercising their shareholder rights and responsibilities [3][4]. - They commit to cooperating actively in significant company decisions and adhering to relevant legal obligations as consistent action persons [4]. - The agreement is effective for twelve months from the date of signing [5]. Group 3: Impact of the Agreement - The renewal of the agreement does not change the actual control of the company, which remains with Fang Yongsheng, Liang Xilin, and Wang Guoqiang, ensuring stability in control and continuity in strategic and operational policies [6].

Core Viewpoint - Huaxia Eye Hospital (301267.SZ) has signed a supplementary agreement to extend the validity of the existing concerted action agreement by three years, until November 7, 2028, to maintain the stability of its corporate governance structure and improve decision-making efficiency [1] Shareholding Structure - Mr. Su Qingcan, the chairman and general manager of the company, directly holds 255,405,989 shares, accounting for 30.41% of the total shares [1] - Through holding 84% of Huaxia Medical Investment (Xiamen) Co., Ltd., the largest shareholder, Mr. Su controls an additional 214,841,769 shares, representing 25.58% of the total shares [1] - In total, Mr. Su holds 470,247,758 shares, which is 55.98% of the total shares, either directly or indirectly [1] Concerted Action Agreement - Ms. Su Shihua is recognized as a concerted actor with Mr. Su Qingcan, and together they hold a total of 529,194,600 shares, which constitutes 63.00% of the total shares [1]

Group 1 - The actual controllers of Zhongyuan Co., Ltd. signed a voting rights entrustment agreement, transferring a total of 100.5 million shares' voting rights to Zhu Shuangquan and Zhu Shunquan, resulting in them holding 20.71% of the voting rights after the agreement takes effect [1] - Zhu Shuangquan, Zhu Shunquan, and Zhu Mengqian signed a concerted action agreement, collectively holding 25.63% of the voting rights, leading to a change in the actual controllers of the company [1] - The company plans to issue up to 61.35 million shares, not exceeding 30% of the total share capital before the issuance, with a total fundraising amount not exceeding 500 million RMB [2] Group 2 - The company's stock will resume trading on November 3, 2025, following an application to the Shenzhen Stock Exchange [3]

Core Viewpoint - The report details the equity change of Shouhua Gas Technology (Shanghai) Co., Ltd., indicating that Shanghai Houde Miaojing Business Consulting Co., Ltd. has increased its shareholding, aiming to gain control over the company and enhance its operational efficiency and governance structure [1][14]. Group 1: Equity Change Details - Shanghai Houde plans to acquire 27,216,000 shares, representing 10.02% of the total share capital of Shouhua Gas, from Ganzhou Haide Investment Partnership [19]. - The total payment for the shares is set at RMB 330.6744 million, with the first payment of RMB 100 million already made [20][23]. - After the transaction, the combined shareholding of Shanghai Houde, Shanxi Huijing, and Liu Jinli will amount to 35,165,308 shares, or 12.94% of the total share capital [18]. Group 2: Stakeholder Information - Liu Qingli is identified as the actual controller of both Shanghai Houde and Shanxi Huijing, establishing a unified action relationship among the stakeholders [14][17]. - Shanxi Huijing holds 100% of its shares under the control of China Panorama Energy Ltd., with Liu Qingli as the actual controller [9][10]. - Liu Jinli directly holds 17,183,968 shares, accounting for 6.32% of the total share capital [17]. Group 3: Future Plans and Governance - The purpose of the equity change is to recognize the value and development prospects of Shouhua Gas, with plans to improve operational efficiency and governance [14]. - The stakeholders commit to not transferring the acquired shares within 18 months post-acquisition and may consider further acquisitions based on business needs [14][23]. - No immediate plans for significant changes to the main business operations of Shouhua Gas have been outlined for the next 12 months [23].

Core Viewpoint - The report details the equity change of Daheng New Era Technology Co., Ltd., highlighting the signing of a concerted action agreement between Li Rongrong and Zhou Zhengchang, resulting in an increase in their combined shareholding to 9.26% of the company's total equity [1][5][7]. Group 1: Equity Change Details - The equity change is due to the signing of a concerted action agreement on August 16, 2025, which allows Li Rongrong and Zhou Zhengchang to act together in shareholder meetings and board decisions [6][9]. - Prior to the agreement, Li Rongrong held 27,460,000 shares (6.29% of total equity) and Zhou Zhengchang held 13,000,000 shares (2.98% of total equity) [7][8]. - After the agreement, their combined shareholding increased to 40,460,000 shares, representing 9.26% of the total equity [7][8]. Group 2: Purpose and Future Plans - The purpose of the equity change is to protect the mutual interests of the parties involved and to ensure a unified decision-making process in the company's governance [6][9]. - There are currently no plans to increase their shareholding further within the next 12 months [7][15]. - The parties have no intentions to change the company's main business or make significant adjustments to its operations in the near future [15][17]. Group 3: Financial and Legal Compliance - The funds used for acquiring shares were sourced from personal or self-raised funds, with no involvement from the company or its affiliates [13][14]. - The report confirms that the parties have complied with all relevant legal and regulatory requirements, ensuring the accuracy and completeness of the disclosures made [20][21].

Core Viewpoint - The Anhui Securities Regulatory Commission has ordered Oriental Materials' major shareholders to rectify their actions due to discrepancies in information disclosure, prohibiting them from exercising voting rights on their shares until corrections are made [1][5]. Group 1: Shareholder Actions - In May, Jiangsu Teliang New Materials Technology Co., Ltd. acquired a 5.96% stake in Oriental Materials through auction and stated no plans for further share changes within the next 12 months [2]. - Hongsheng Dingrong Investment Management Partnership, established on May 29, participated in a judicial auction for 3.49% of Oriental Materials' shares, increasing its holdings to 7.0241 million shares by June 30 [3][4]. Group 2: Regulatory Findings - The Anhui Securities Regulatory Commission found that Teliang and Hongsheng Dingrong violated regulations by not disclosing their status as concerted actors in their May 30 report [5]. - The commission has mandated that both companies suspend acquisition activities and submit a written rectification report within 30 days of receiving the regulatory decision [5]. Group 3: Legal and Compliance Considerations - The determination of when a concerted action relationship is established can vary, with two potential methods: factual establishment or formal disclosure [7]. - Legal experts suggest that if decisions and communications occurred before the May 30 report, the concerted action could be recognized from that date rather than the later announcement on June 6 [8].